UMIN ID: UMIN000008786
Registered date:28/08/2012
WJOG6510GTR: Study of genetic biomarkers to predict efficacy in patients with wild-type KRAS metastatic colorectal cancer receiving Panitumumab + Irinotecan or Cetuximab + Irinotecan
Basic Information
Recruitment status | Complete: follow-up complete |
---|---|
Health condition(s) or Problem(s) studied | Advanced colorectal cancer |
Date of first enrollment | 2013/05/01 |
Target sample size | 120 |
Countries of recruitment | Japan |
Study type | Observational |
Intervention(s) |
Outcome(s)
Primary Outcome | To evaluate the correlation between the efficacy or safety and the genetic polymorphism in patients with cetuximab plus irinotecan or panitumumab plus irinotecan therapy. |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | 20years-old |
---|---|
Age maximum | Not applicable |
Gender | Male and Female |
Include criteria | |
Exclude criteria | Not applicable |
Related Information
Primary Sponsor | West Japan Oncology Group |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | None |
Secondary ID(s) |
Contact
public contact | |
Name | Shinichiro Nakamura |
Address | Namba Plaza Bldg.3F 1-5-7,Motomachi Naniwa-ku, Osaka Japan |
Telephone | 06-6633-7400 |
datacenter@wjog.jp | |
Affiliation | West Japan Oncology Group datacenter |
scientific contact | |
Name | Hiroya Taniguchi |
Address | 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681 Japan Japan |
Telephone | 055-989-5222 |
h.taniguchi@aichi-cc.jp | |
Affiliation | Aichi Cancer Center Hospital Department of Clinical Oncology |